Company research
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 315545Updated Sep 27, 2026
SecurityPVCT · OTC · equity
Name history
PROVECTUS PHARMACEUTICALS INC · through Dec 18, 2013PROVECTUS PHARMACEUTICAL INC · through May 15, 2002ZAMAGE DIGITAL IMAGING INC · through Apr 1, 2002SPM GROUP INC · through Nov 14, 2001
PVCT price & chart
Loading TradingView…
OTC:PVCT on TradingView ↗In the news
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders ↗
Recent filings
10-Q filing
SCHEDULE 13D/A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 697,502Source | 1,006,259Source | 1,448,843Source | 2,037,246Source |
| Property, Plant and Equipment, NetUSD | 3,000Source | 4,863Source | 12,020Source | 20,941Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 251,291Source | 307,442Source | 76,576Source | 21,605Source |
| Assets, CurrentUSD | 567,874Source | 976,772Source | 1,364,797Source | 1,899,182Source |
| Prepaid Expense and Other Assets, CurrentUSD | 316,583Source | 487,046Source | 337,522Source | — |
| Operating Lease, Right-of-Use AssetUSD | 126,628Source | 24,624Source | 72,026Source | 117,123Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,000,220Source | 6,975,484Source | 9,042,194Source | 8,265,756Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 420,280Source | 420,280Source | 419,522Source | 419,497Source |
| Additional Paid in CapitalUSD | 256,179,846Source | 251,090,027Source | 244,714,967Source | 242,954,193Source |
| Retained Earnings (Accumulated Deficit)USD | -262,853,812Source | -257,422,961Source | -252,690,409Source | -249,588,641Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -60,191Source | -60,741Source | -60,165Source | -35,679Source |
| Stockholders' Equity Attributable to ParentUSD | -6,298,737Source | -5,959,332Source | -7,593,351Source | -6,228,510Source |
| Liabilities and EquityUSD | 697,502Source | 1,006,259Source | 1,448,843Source | 2,037,246Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,897,378Source | 6,975,484Source | 9,016,895Source | 8,192,380Source |
| Operating Lease, Liability, CurrentUSD | 48,083Source | 25,299Source | 48,077Source | 44,422Source |
| Accounts Payable, CurrentUSD | 716,220Source | 1,106,551Source | 1,675,891Source | 2,094,258Source |
| Operating Lease, Liability, NoncurrentUSD | 79,221Source | — | 25,299Source | 73,376Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -3,981Source | -9,893Source | — | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | — | 336,108Source | 953,248Source | 1,510,958Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -5,505,124Source | -4,762,137Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,237,546Source | 1,280,776Source | 2,850Source | 3,025Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -3,325,991Source | -3,284,091Source | -2,571,978Source | -3,041,472Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,087,006Source | 2,747,865Source | 2,191,555Source | 1,367,841Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -238,435Source | -537,073Source | -404,908Source | -1,675,235Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,305Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,237,546Source | 1,280,786Source | — | — |
| DepreciationUSD | 1,863Source | 7,157Source | 8,921Source | 10,895Source |
| General and Administrative ExpenseUSD | 3,733,597Source | 3,150,397Source | 1,709,720Source | 2,027,628Source |
| Net Income (Loss) Attributable to ParentUSD | -5,430,851Source | -4,732,552Source | -3,101,768Source | -3,554,683Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -74,273Source | -29,585Source | — | — |
| Nonoperating Income (Expense)USD | -210,359Source | -229,753Source | -200,518Source | -126,737Source |
| Operating ExpensesUSD | 5,630,873Source | 5,149,524Source | 3,458,960Source | 4,416,988Source |
| Operating Lease, ExpenseUSD | 47,523Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 336,108Source | 617,140Source | 557,710Source | 989,042Source |
| Operating Income (Loss)USD | -5,294,765Source | -4,532,384Source | -2,901,250Source | -3,427,946Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -5,505,162Source | -4,762,137Source | -3,125,995Source | -3,554,683Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -74,273Source | -29,585Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,430,851Source | -4,732,552Source | -3,101,768Source | -3,554,683Source |
| Earnings Per Share, BasicUSD per share | -0.01Source | -0.01Source | -0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | -0.01Source | -0.01Source | -0.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 420,279,879Source | 419,810,059Source | 419,508,146Source | 419,470,338Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 420,279,879Source | 419,810,059Source | 419,508,146Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -442,684Source | 331,140Source | -704,628Source | 670,693Source |
| General and Administrative ExpenseUSD | 3,733,597Source | 3,150,397Source | 1,709,720Source | 2,027,628Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -5,505,122Source | -4,763,882Source | -3,116,233Source | -3,550,182Source |
| Interest ExpenseUSD | 5,338Source | 13,591Source | 5,650Source | — |
| Interest Income (Expense), NetUSD | -210,359Source | -239,073Source | -216,214Source | -163,691Source |
| Nonoperating Income (Expense)USD | -210,359Source | -229,753Source | -200,518Source | -126,737Source |
| Operating ExpensesUSD | 5,630,873Source | 5,149,524Source | 3,458,960Source | 4,416,988Source |
| Operating Lease, ExpenseUSD | 47,523Source | — | — | — |
| Research and Development ExpenseUSD | 1,897,276Source | 1,999,127Source | 1,749,240Source | 2,389,360Source |
Filing attachments
ex99-1.htm · 8-K · 2026-04-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── KNOXVILLE, T…
Read attachment ↗ex4-1.htm · 8-K · 2025-01-22
EX-4.1 2 ex4-1.htm Exhibit 4.1 THIS UNSECURED CONVERTIBLE PROMISSORY NOTE (THIS “ NOTE ”) HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“ ACT ”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION APPLIES. THEREFORE, NO SALE OR TRANSFER OF THIS NOTE SHALL BE MADE, NO ATTE…
Read attachment ↗